BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol. 2013;59:769-779. [PMID: 23792028 DOI: 10.1016/j.jhep.2013.06.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
2 Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases. Int J Mol Sci 2020;21:E5497. [PMID: 32752088 DOI: 10.3390/ijms21155497] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
3 Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer 2019;8:387-402. [PMID: 31768347 DOI: 10.1159/000492628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther 2014;39:1204-12. [DOI: 10.1111/apt.12731] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
5 Grønbæk H, Rødgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, Solà E, Domenicali M, Piano S, Vilstrup H, Møller HJ; CANONIC study investigators of the EASL-CLIF Consortium. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol 2016;64:813-22. [PMID: 26639396 DOI: 10.1016/j.jhep.2015.11.021] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
6 Frión-Herrera Y, Gabbia D, Cuesta-Rubio O, De Martin S, Carrara M. Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. Life Sci 2019;235:116817. [PMID: 31476309 DOI: 10.1016/j.lfs.2019.116817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
7 Rødgaard-hansen S, St. George A, Kazankov K, Bauman A, George J, Grønbæk H, Jon Møller H. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation 2017;77:498-504. [DOI: 10.1080/00365513.2017.1346823] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clin Cancer Res. 2017;23:7333-7339. [PMID: 28928158 DOI: 10.1158/1078-0432.ccr-17-0950] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
9 Zhi Y, Gao P, Xin X, Li W, Ji L, Zhang L, Zhang X, Zhang J. Clinical significance of sCD163 and its possible role in asthma (Review). Mol Med Rep 2017;15:2931-9. [PMID: 28350095 DOI: 10.3892/mmr.2017.6393] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
10 Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653-1666. [PMID: 30902885 DOI: 10.1136/gutjnl-2019-318419] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 27.7] [Reference Citation Analysis]
11 Sekiguchi T, Umemura T, Fujimori N, Shibata S, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One 2015;10:e0131658. [PMID: 26110613 DOI: 10.1371/journal.pone.0131658] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
12 Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, Wu L, Hou X, Lu J, Bao Y, Jia W. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci Rep 2017;7:5095. [PMID: 28698650 DOI: 10.1038/s41598-017-05257-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. Journal of Hepatology 2015;62:863-70. [DOI: 10.1016/j.jhep.2014.11.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
14 Huang Y, Yang L, Lin Y, Chang X, Wu H, Chen Y. Prognostic value of non-invasive serum Cytokeratin 18 detection in gastrointestinal cancer: a meta-analysis. J Cancer 2019;10:4814-23. [PMID: 31598152 DOI: 10.7150/jca.31408] [Reference Citation Analysis]
15 Lin MW, Yang CY, Kuo SW, Wu CT, Chang YL, Yang PC. The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas. Ann Surg Oncol 2016;23:3071-81. [PMID: 27150441 DOI: 10.1245/s10434-016-5244-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A, Groselj-Strele A, Stauber RE, Fickert P, Stiegler P, Møller HJ, Grønbaek H, Stadlbauer V. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Aliment Pharmacol Ther 2018;47:657-64. [PMID: 29266346 DOI: 10.1111/apt.14474] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
17 Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H. Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Aliment Pharmacol Ther 2016;44:747-54. [PMID: 27485159 DOI: 10.1111/apt.13758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, Li JL. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer 2019;121:22-33. [PMID: 31130723 DOI: 10.1038/s41416-019-0482-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
19 Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients. J Viral Hepat. 2016;23:267-273. [PMID: 26554542 DOI: 10.1111/jvh.12488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
20 Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157-167. [PMID: 26452628 DOI: 10.1136/gutjnl-2015-310514] [Cited by in Crossref: 209] [Cited by in F6Publishing: 233] [Article Influence: 29.9] [Reference Citation Analysis]
21 Han Y, Guo W, Ren T, Huang Y, Wang S, Liu K, Zheng B, Yang K, Zhang H, Liang X. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. Cancer Lett 2019;440-441:116-25. [PMID: 30343113 DOI: 10.1016/j.canlet.2018.10.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
22 Marquardt JU, Edlich F. Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. Front Oncol 2019;9:1421. [PMID: 31921676 DOI: 10.3389/fonc.2019.01421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zhang Y, Huang C, Nie Y, Liu Q, Xiao N, Liu L, Zhu X. Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. Front Med (Lausanne) 2021;8:698502. [PMID: 34336902 DOI: 10.3389/fmed.2021.698502] [Reference Citation Analysis]
24 Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908. [PMID: 24260507 DOI: 10.1371/journal.pone.0080908] [Cited by in Crossref: 286] [Cited by in F6Publishing: 293] [Article Influence: 31.8] [Reference Citation Analysis]
25 Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scand J Clin Lab Invest 2016;76:64-73. [PMID: 26549495 DOI: 10.3109/00365513.2015.1099722] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
26 Ronen S, Rothschild M, Suster S. The interstitial variant of granuloma annulare: Clinicopathologic study of 69 cases with a comparison with conventional granuloma annulare. J Cutan Pathol 2019;46:471-8. [DOI: 10.1111/cup.13455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang Z, Ke ZF, Lu XF, Luo CJ, Liu YD, Lin ZW, Wang LT. The clue of a possible etiology about spontaneous regression of hepatocellular carcinoma: a perspective on pathology. Onco Targets Ther 2015;8:395-400. [PMID: 25709471 DOI: 10.2147/OTT.S79102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113:756-762. [PMID: 26270232 DOI: 10.1038/bjc.2015.227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
29 Finkelmeier F, Bettinger D, Köberle V, Schultheiß M, Zeuzem S, Kronenberger B, Piiper A, Waidmann O. Single measurement of hemoglobin predicts outcome of HCC patients. Med Oncol 2014;31:806. [PMID: 24326985 DOI: 10.1007/s12032-013-0806-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
30 Fei Q, Pan Y, Yu X, Lin R, Lin X, Huang H. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma. Journal of Pancreatology 2020;3:147-53. [DOI: 10.1097/jp9.0000000000000055] [Reference Citation Analysis]
31 Wang X, Wu Y, Wen D, Wu LY, Zhao Y, He Y, Yang H. An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma. Med Sci Monit 2020;26:e921786. [PMID: 32527991 DOI: 10.12659/MSM.921786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Finkelmeier F, Canli Ö, Tal A, Pleli T, Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR, Waidmann O. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European Journal of Cancer 2016;59:152-9. [DOI: 10.1016/j.ejca.2016.03.002] [Cited by in Crossref: 99] [Cited by in F6Publishing: 110] [Article Influence: 16.5] [Reference Citation Analysis]
33 Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat 2015;22:427-32. [DOI: 10.1111/jvh.12309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
34 Ismail SA, El Saadany Sh, Ziada DH, Zakaria SS, Mayah WW, Elashry H, Arafa M, Elmashad N. Cytokeratin-18 in Diagnosis of HCC in Patients with Liver Cirrhosis. Asian Pac J Cancer Prev 2017;18:1105-11. [PMID: 28547948 DOI: 10.22034/APJCP.2017.18.4.1105] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, Qian J, Xu Z, Zhang K, Su R, Guo D, Zhou L, Zheng S. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. OncoImmunology 2022;11:2073010. [DOI: 10.1080/2162402x.2022.2073010] [Reference Citation Analysis]
36 Grammatikos G, Schoell N, Ferreirós N, Bon D, Herrmann E, Farnik H, Köberle V, Piiper A, Zeuzem S, Kronenberger B, Waidmann O, Pfeilschifter J. Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget 2016;7:18095-105. [PMID: 26933996 DOI: 10.18632/oncotarget.7741] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
37 Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X. Clinicopathologic and prognostic significance of tumor-associated macrophages in patients with hepatocellular carcinoma: A meta-analysis. PLoS One 2019;14:e0223971. [PMID: 31618252 DOI: 10.1371/journal.pone.0223971] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
38 Liao WQ, Qi YL, Wang L, Dong XM, Xu T, Ding CD, Liu R, Liang WC, Lu LT, Li H, Li WF, Luo GB, Lu XC. Recql5 protects against lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 2015; 21(36): 10375-10384 [PMID: 26420964 DOI: 10.3748/wjg.v21.i36.10375] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
39 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Reference Citation Analysis]
40 Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Cytokeratin 18-based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients. Liver Int 2016;36:1464-72. [DOI: 10.1111/liv.13117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
41 Lorente L, Rodriguez ST, Sanz P, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Barrera MA. Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. Int J Mol Sci 2016;17:E1524. [PMID: 27618033 DOI: 10.3390/ijms17091524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma. World J Gastroenterol 2018; 24(37): 4230-4242 [PMID: 30310256 DOI: 10.3748/wjg.v24.i37.4230] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
43 Sakr MA, Mohamed KAH, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00090-y] [Reference Citation Analysis]
44 Asimakopoulou A, Weiskirchen S, Weiskirchen R. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front Physiol 2016;7:430. [PMID: 27729871 DOI: 10.3389/fphys.2016.00430] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
45 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Degroote H, Van Dierendonck A, Geerts A, Van Vlierberghe H, Devisscher L. Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma. J Immunol Res 2018;2018:7819520. [PMID: 30410942 DOI: 10.1155/2018/7819520] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
47 Peng F, Li H, You Q, Li H, Wu D, Jiang C, Deng G, Li Y, Li Y, Wu Y. CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. Biomed Res Int 2017;2017:5019367. [PMID: 28386553 DOI: 10.1155/2017/5019367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kakoschky B, Pleli T, Schmithals C, Zeuzem S, Brüne B, Vogl TJ, Korf HW, Weigert A, Piiper A. Selective targeting of tumor associated macrophages in different tumor models. PLoS One 2018;13:e0193015. [PMID: 29447241 DOI: 10.1371/journal.pone.0193015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
49 Qian S, Zhang H, Dai H, Ma B, Tian F, Jiang P, Gao H, Sha X, Sun X. Is sCD163 a Clinical Significant Prognostic Value in Cancers? A Systematic Review and Meta-Analysis. Front Oncol 2020;10:585297. [PMID: 33240816 DOI: 10.3389/fonc.2020.585297] [Reference Citation Analysis]
50 Raszeja-Wyszomirska J, Niewiński G, Graczyńska A, Morawiec S, Janik MK, Kornasiewicz O. Clinical Implication of Plasma CD163 in Patients With Acute-on-Chronic Liver Failure. Transplant Proc 2022:S0041-1345(22)00192-0. [PMID: 35523597 DOI: 10.1016/j.transproceed.2022.02.048] [Reference Citation Analysis]
51 Wan S, Lei Y, Li M, Wu B. A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes. Hepatol Int 2021. [PMID: 34449009 DOI: 10.1007/s12072-021-10248-w] [Reference Citation Analysis]
52 Morris KL, Tugwood JD, Khoja L, Lancashire M, Sloane R, Burt D, Shenjere P, Zhou C, Hodgson C, Ohtomo T. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014;74:323-332. [PMID: 24923562 DOI: 10.1007/s00280-014-2508-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
53 Zheng C, Liu X, Chen L, Xu Z, Shao J. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:59638-47. [PMID: 28938667 DOI: 10.18632/oncotarget.19559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
54 Isaac A, Mohamed SM, Ahmed OA, Hassan AGM, Rasmy HS. Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00078-5] [Reference Citation Analysis]